MiniMed Group (NASDAQ:MMED) Research Coverage Started at The Goldman Sachs Group

The Goldman Sachs Group assumed coverage on shares of MiniMed Group (NASDAQ:MMED) in a report issued on Tuesday, Marketbeat reports. The brokerage issued a buy rating and a $24.00 target price on the stock.

Several other research analysts also recently issued reports on MMED. William Blair began coverage on shares of MiniMed Group in a research note on Tuesday. They issued an “outperform” rating on the stock. Piper Sandler started coverage on shares of MiniMed Group in a research report on Tuesday. They set a “neutral” rating and a $16.00 price target for the company. BTIG Research began coverage on shares of MiniMed Group in a report on Tuesday. They issued a “buy” rating and a $25.00 price objective for the company. Morgan Stanley assumed coverage on MiniMed Group in a research note on Tuesday. They set an “overweight” rating and a $19.00 target price on the stock. Finally, Evercore assumed coverage on MiniMed Group in a report on Tuesday. They issued an “outperform” rating and a $20.00 target price for the company. Eleven investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, MiniMed Group presently has an average rating of “Moderate Buy” and a consensus target price of $22.45.

MiniMed Group Stock Down 3.2%

Shares of MiniMed Group stock opened at $14.01 on Tuesday. MiniMed Group has a 1 year low of $13.52 and a 1 year high of $20.48.

Trending Headlines about MiniMed Group

Here are the key news stories impacting MiniMed Group this week:

• Positive Sentiment: Barclays set an “overweight” rating with a $26 price target (~85% upside vs. current price), giving a clear bullish analyst catalyst. Article Title
• Neutral Sentiment: Goldman Sachs initiated coverage on MMED (coverage note published; no widely reported price target in the release). Article Title
• Neutral Sentiment: William Blair began coverage on MMED (initial research coverage announced). Article Title
• Neutral Sentiment: Evercore initiated coverage on MMED (coverage note released). Article Title
• Neutral Sentiment: Wells Fargo initiated coverage on MMED. Article Title
• Neutral Sentiment: Piper Sandler initiated coverage on MMED. Article Title
• Neutral Sentiment: Deutsche Bank began coverage on MMED. Article Title
• Neutral Sentiment: Citigroup initiated coverage on MMED. Article Title
• Neutral Sentiment: BTIG Research initiated coverage on MMED. Article Title
• Neutral Sentiment: Mizuho began coverage on MMED. Article Title
• Neutral Sentiment: Morgan Stanley began coverage on MMED. Article Title
• Neutral Sentiment: Bank of America initiated coverage on MMED. Article Title

About MiniMed Group

We are a scaled global medical technology company that develops, manufactures, and markets a comprehensive suite of solutions for the management of diabetes. Since our founding more than 40 years ago, we have pioneered groundbreaking innovation and served the needs of our customers across the globe in service of our mission to make every day a better day for people with diabetes. Today, we are the only player in the market that commercializes all parts of an integrated diabetes management system.